vs
Side-by-side financial comparison of Hippo Holdings Inc. (HIPO) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
Hippo Holdings Inc. is the larger business by last-quarter revenue ($120.4M vs $75.5M, roughly 1.6× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 18.2%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $9.1M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 18.9%).
Hippo Valley Estate is a sugar estate found near the town of Chiredzi in Chiredzi District of southeastern Zimbabwe, on the Runde River near the border with Mozambique.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
HIPO vs PBYI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $120.4M | $75.5M |
| Net Profit | $6.0M | — |
| Gross Margin | — | 69.3% |
| Operating Margin | 5.6% | 22.7% |
| Net Margin | 5.0% | — |
| Revenue YoY | 18.2% | 27.7% |
| Net Profit YoY | -86.4% | — |
| EPS (diluted) | $0.31 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $120.4M | $75.5M | ||
| Q3 25 | $120.6M | $54.5M | ||
| Q2 25 | $117.3M | $52.4M | ||
| Q1 25 | $110.3M | $46.0M | ||
| Q4 24 | $101.9M | $59.1M | ||
| Q3 24 | $95.5M | $80.5M | ||
| Q2 24 | $89.6M | $47.1M | ||
| Q1 24 | $85.1M | $43.8M |
| Q4 25 | $6.0M | — | ||
| Q3 25 | $98.1M | $8.8M | ||
| Q2 25 | $1.3M | $5.9M | ||
| Q1 25 | $-47.7M | $3.0M | ||
| Q4 24 | $44.2M | — | ||
| Q3 24 | $-8.5M | $20.3M | ||
| Q2 24 | $-40.5M | $-4.5M | ||
| Q1 24 | $-35.7M | $-4.8M |
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
| Q4 25 | 5.6% | 22.7% | ||
| Q3 25 | 81.3% | 17.6% | ||
| Q2 25 | 3.4% | 12.7% | ||
| Q1 25 | -41.3% | 8.7% | ||
| Q4 24 | 46.3% | 22.6% | ||
| Q3 24 | -5.4% | 27.4% | ||
| Q2 24 | -40.7% | -4.6% | ||
| Q1 24 | -38.7% | -5.3% |
| Q4 25 | 5.0% | — | ||
| Q3 25 | 81.3% | 16.2% | ||
| Q2 25 | 1.1% | 11.2% | ||
| Q1 25 | -43.2% | 6.5% | ||
| Q4 24 | 43.4% | — | ||
| Q3 24 | -8.9% | 25.2% | ||
| Q2 24 | -45.2% | -9.6% | ||
| Q1 24 | -42.0% | -11.0% |
| Q4 25 | $0.31 | $0.26 | ||
| Q3 25 | $3.77 | $0.17 | ||
| Q2 25 | $0.05 | $0.12 | ||
| Q1 25 | $-1.91 | $0.06 | ||
| Q4 24 | $1.81 | $0.40 | ||
| Q3 24 | $-0.34 | $0.41 | ||
| Q2 24 | $-1.64 | $-0.09 | ||
| Q1 24 | $-1.47 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $218.3M | $97.5M |
| Total DebtLower is stronger | — | $22.7M |
| Stockholders' EquityBook value | $436.1M | $130.3M |
| Total Assets | $1.9B | $216.3M |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $218.3M | $97.5M | ||
| Q3 25 | $247.7M | $94.4M | ||
| Q2 25 | $198.9M | $96.0M | ||
| Q1 25 | $140.9M | $93.2M | ||
| Q4 24 | $197.6M | $101.0M | ||
| Q3 24 | $191.2M | $96.7M | ||
| Q2 24 | $175.9M | $96.8M | ||
| Q1 24 | $223.4M | $107.2M |
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
| Q4 25 | $436.1M | $130.3M | ||
| Q3 25 | $421.5M | $115.3M | ||
| Q2 25 | $332.5M | $104.7M | ||
| Q1 25 | $322.8M | $97.1M | ||
| Q4 24 | $362.1M | $92.1M | ||
| Q3 24 | $326.4M | $71.1M | ||
| Q2 24 | $322.6M | $48.5M | ||
| Q1 24 | $351.2M | $51.0M |
| Q4 25 | $1.9B | $216.3M | ||
| Q3 25 | $1.9B | $202.9M | ||
| Q2 25 | $1.7B | $194.9M | ||
| Q1 25 | $1.5B | $196.2M | ||
| Q4 24 | $1.5B | $213.3M | ||
| Q3 24 | $1.5B | $220.7M | ||
| Q2 24 | $1.5B | $205.0M | ||
| Q1 24 | $1.5B | $214.1M |
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.2M | $14.4M |
| Free Cash FlowOCF − Capex | $9.1M | $14.4M |
| FCF MarginFCF / Revenue | 7.6% | 19.1% |
| Capex IntensityCapex / Revenue | 0.1% | 0.0% |
| Cash ConversionOCF / Net Profit | 1.53× | — |
| TTM Free Cash FlowTrailing 4 quarters | $14.8M | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.2M | $14.4M | ||
| Q3 25 | $16.9M | $9.7M | ||
| Q2 25 | $24.7M | $14.1M | ||
| Q1 25 | $-35.6M | $3.6M | ||
| Q4 24 | $47.5M | $15.6M | ||
| Q3 24 | $46.8M | $11.0M | ||
| Q2 24 | $-10.6M | $1.0M | ||
| Q1 24 | $17.7M | $11.2M |
| Q4 25 | $9.1M | $14.4M | ||
| Q3 25 | $16.8M | $9.7M | ||
| Q2 25 | $24.6M | $14.1M | ||
| Q1 25 | $-35.7M | $3.6M | ||
| Q4 24 | $47.2M | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | $-10.7M | $1.0M | ||
| Q1 24 | $17.6M | — |
| Q4 25 | 7.6% | 19.1% | ||
| Q3 25 | 13.9% | 17.7% | ||
| Q2 25 | 21.0% | 26.8% | ||
| Q1 25 | -32.4% | 7.7% | ||
| Q4 24 | 46.3% | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | -11.9% | 2.1% | ||
| Q1 24 | 20.7% | — |
| Q4 25 | 0.1% | 0.0% | ||
| Q3 25 | 0.1% | 0.0% | ||
| Q2 25 | 0.1% | 0.0% | ||
| Q1 25 | 0.1% | 0.1% | ||
| Q4 24 | 0.3% | 0.0% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.1% | 0.0% | ||
| Q1 24 | 0.1% | 0.0% |
| Q4 25 | 1.53× | — | ||
| Q3 25 | 0.17× | 1.10× | ||
| Q2 25 | 19.00× | 2.41× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
